HIMS
Hims & Hers Health, Inc.
NYSE · Healthcare · Medical - Equipment & Services · US
$28.15
+0.29%Oct 14, 2026, 22:46 UTC
Hims & Hers Health shares fell 6.7% to $27.72 from the preceding trading day.
Source:Oct 12, 2026, 20:05 UTC
Hims & Hers Health announced that it will report third-quarter 2026 financial results after market close on November 9, 2026, and host a conference call at 5:00 p.m. ET that day.
Source:Oct 12, 2026, 19:00 UTC
Hims & Hers announced the launch of Hers in Australia, offering women’s care programs for hair, menopause and perimenopause, and weight loss.
Source:Oct 8, 2026, 22:46 UTC
Hims & Hers Health shares closed at $28.06, down 5.01% from the previous trading session.
Source:Oct 7, 2026, 20:24 UTC
Hims & Hers Health appointed Jonathan M. Franklin as chief accounting officer effective October 5, 2026, and as principal accounting officer effective October 9, 2026; Irene Becklund resigned as principal accounting officer effective October 9, 2026.
Source:Oct 2, 2026, 21:45 UTC
Bayer announced plans to invest $2.2 billion in a new pharmaceutical manufacturing campus in New Albany, Ohio, expected to create about 600 jobs with the first module operational in 2031.
Sep 23, 2026, 22:45 UTC
Hims & Hers Health, Inc. (HIMS) shares fell 6.7% to close at $28.39 in the most recent trading session.
Source:Sep 23, 2026, 12:30 UTC
The U.S. Federal Trade Commission filed a lawsuit alleging that telehealth company Hims & Hers used deceptive practices, including disclosing customers' health data, enrolling them in hard-to-cancel subscriptions, and bypassing real-time doctor consultations.
Sep 22, 2026, 19:00 UTC
MAHA Center, a nonprofit tied to HHS Secretary Robert F. Kennedy Jr., solicited corporate sponsorship payments of up to $300,000 for the Sept. 29 MAHA Summit in exchange for access to top U.S. health officials including Kennedy and CMS head Mehmet Oz.
Source:Sep 17, 2026, 20:30 UTC
A securities fraud class action lawsuit, Velanki v. Hims & Hers Health, Inc., was filed against Hims & Hers Health in the U.S. District Court for the Northern District of California over alleged misstatements about its privacy practices, with a November 2, 2026 deadline for lead plaintiff status.
Source:Sep 14, 2026, 17:30 UTC
Robbins LLP announced a class action filed on behalf of investors who purchased Hims & Hers Health, Inc. securities between August 4, 2025 and July 29, 2026, alleging the company shared customers' protected information with advertising platforms and engaged in deceptive advertising practices.
Sep 10, 2026, 20:45 UTC
Kaplan Fox & Kilsheimer LLP announced that a class action lawsuit has been filed against Hims & Hers Health, Inc. on behalf of investors who acquired its securities between August 4, 2025 and July 29, 2026, with a lead plaintiff deadline of November 2, 2026.
Aug 24, 2026, 16:45 UTC
Hims & Hers Health received a warning from Visa due to excessive customer disputes over its weight-loss drug subscription service, leading to its inclusion in Visa's Acquirer Monitoring Program (VAMP).
Aug 11, 2026, 13:45 UTC
Hims & Hers Health announced plans to enter the peptide market within the year to capture demand in the rapidly growing healthcare market.
Source:Jul 24, 2026, 03:40 UTC
An FDA advisory panel voted to recommend easing restrictions on four peptides (BPC-157, KPV, TB-500, MOTS-C), potentially expanding the market for telehealth firms like Hims & Hers Health.
Jul 17, 2026, 20:17 UTC
Hims & Hers Health announced that Chief Accounting Officer Irene Becklund will depart the company effective October 9, 2026.
Source:Jul 8, 2026, 12:34 UTC
Hims & Hers Health acquired Eucalyptus for $1.15 billion, adding 850,000 customers and approximately $450 million of ARR across eight international markets.
Source:Jul 8, 2026, 12:34 UTC
Hims & Hers Health secured a $400 million receivables facility from JPMorgan to improve financial flexibility.
Source:Jul 1, 2026, 18:15 UTC
Hims & Hers Health shares surged 9% on Wednesday.
Source:Jul 1, 2026, 00:00 UTC
Hims & Hers Health, Inc. entered into a Master Receivables Purchase Agreement with JPMorgan Chase Bank, N.A., establishing a $400 million uncommitted facility for the purchase of eligible receivables, and amended its existing revolving credit agreement to permit this transaction.
Jun 4, 2026, 13:00 UTC
Hims & Hers Health appointed Dr. Anant Vinjamoori as Chief Medical Officer of the Hims brand.
Source:Jun 2, 2026, 09:00 UTC
Hims & Hers Health, Inc. completed its acquisition of Eucalyptus, the parent company of Juniper, expanding its weight management care in Germany.
May 21, 2026, 00:00 UTC
Hims & Hers Health, Inc. issued $402.5 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032, comprising $350.0 million initial principal and a $52.5 million option to purchase additional notes, with conversion into Class A Common Stock at an initial rate of 33.8590 shares per $1,000 principal amount.